(Total Views: 476)
Posted On: 02/16/2021 1:08:18 PM
Post# of 153871
Re: Shelly2626 #78140
Shelly,
USA today and major media just discussing viral/spike targeting mAbs, which may have diminished efficacy, similar to the concerns for the current vaccines.
Leronlimab and lenzilumab (if successful) will have no such issues, as they target out immune system, not the virus.
Big pharma writing the narrative until leronlimab proves itself with CD12.
Then control of the story board will be wrested from their hands.
Looking forward to NP's cheesy grin on the from page of the WSJ.
USA today and major media just discussing viral/spike targeting mAbs, which may have diminished efficacy, similar to the concerns for the current vaccines.
Leronlimab and lenzilumab (if successful) will have no such issues, as they target out immune system, not the virus.
Big pharma writing the narrative until leronlimab proves itself with CD12.
Then control of the story board will be wrested from their hands.
Looking forward to NP's cheesy grin on the from page of the WSJ.
(5)
(0)
